Scinovex
review Open AccessTop 1% cited

New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta-Analysis

American Journal of Transplantation · 2004 · Vol. 4(4) · pp. 583–595
Olaf HeiselRochelle HeiselRobert BalshawPaul Keown

Abstract

New onset diabetes mellitus (NODM) is a serious complication of transplantation. This meta-analysis evaluates the reported incidence of NODM after solid organ transplantation in patients receiving CNI treatment. Databases from January 1992 to April 2002 were searched. Fifty-six publications providing NODM incidence data were reviewed. Sixteen prospective, randomized comparative studies providing information on incidence of insulin-dependent diabetes mellitus (IDDM) were subjected to meta-analysis. New onset diabetes mellitus was reported in 13.4% of patients after solid organ transplantation, with a higher incidence in patients receiving tacrolimus than cyclosporine (16.6% vs. 9.8%). This trend was observed across renal, liver, heart and lung transplant groups. Meta-analysis of 16 studies included patients receiving either tacrolimus (n=1636) or cyclosporine (n=1407). The incidence of IDDM was significantly higher among tacrolimus-treated patients (10.4% vs. 4.5%, p<0.00001), an effect observed in renal (9.8% vs. 2.7% p<0.00001) and nonrenal (11.1% vs. 6.2%; p<0.003) groups, and among patients receiving equal doses of concomitant medication in both treatment arms (12.0% vs. 3.0%; p<0.00001). The reported incidence of NODM during the past decade was significantly higher among patients receiving tacrolimus than cyclosporine. These data provide a quantitative foundation for studies designed to reduce the rates of NODM following solid organ transplantation.

Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and OutcomesOrgan Transplantation Techniques and OutcomesMedicineTacrolimusCalcineurinDiabetes mellitusIncidence (geometry)Internal medicineMeta-analysisTransplantationSurgeryEndocrinology

MeSH terms

Diabetes MellitusDiabetes Mellitus, Type 1HumansImmunosuppressive AgentsProspective StudiesRetrospective StudiesTime FactorsOrgan TransplantationTacrolimusCyclosporineCalcineurin Inhibitors

Funding

  • Novartis Pharma
Citations
504
FWCI
15.69
field-weighted impact
References
109
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.